Compositions and formulations comprising a non-neutralized tocol phosphate and a vitamin A compound, which are suitable for the treatment of inflammation and/or infection in breast or udder tissue, more particularly in a mammary gland, reducing the somatic cell count in a lactating subject and suppl
Compositions and formulations comprising a non-neutralized tocol phosphate and a vitamin A compound, which are suitable for the treatment of inflammation and/or infection in breast or udder tissue, more particularly in a mammary gland, reducing the somatic cell count in a lactating subject and supplementing vitamin E levels in a subject.
대표청구항▼
1. A method for reducing somatic cell count in a lactating subject comprising administering a formulation to the lactating subject, wherein the formulation comprises a non-neutralised tocol phosphate, a vitamin A compound, and a hydrophobic delivery vehicle, wherein the non-neutralised tocol phospha
1. A method for reducing somatic cell count in a lactating subject comprising administering a formulation to the lactating subject, wherein the formulation comprises a non-neutralised tocol phosphate, a vitamin A compound, and a hydrophobic delivery vehicle, wherein the non-neutralised tocol phosphate is a combination of a non-neutralised mono-(tocopheryl) phosphate and a non-neutralised di-(tocopheryl) phosphate. 2. A method for treating inflammation and/or infection in breast or udder tissue comprising administering a formulation to a subject in need thereof, wherein the formulation comprises a non-neutralised tocol phosphate, a vitamin A compound, and a hydrophobic delivery vehicle, wherein the non-neutralised tocol phosphate is a combination of a non-neutralised mono-(tocopheryl) phosphate and a non-neutralised di-(tocopheryl) phosphate. 3. The method of claim 2 wherein the breast or udder tissue is a mammary gland. 4. The method of claim 2 wherein the inflammation and/or infection is mastitis. 5. The method of claim 2 wherein the subject is selected from humans, domestic mammals including companion animals, working animals, livestock, and zoological/park mammals. 6. The method of claim 2 wherein the combination of the non-neutralised mono-(tocopheryl) phosphate and the non-neutralised di-(tocopheryl) phosphate comprises: (a) a compound selected from the group consisting of non-neutralised mono-(tocopheryl) phosphate, non-neutralised mono-(tocopheryl) phosphate monosodium salt, non-neutralised mono-(tocopheryl) phosphate disodium salt, non-neutralised mono-(tocopheryl) phosphate monopotassium salt, non-neutralised mono-(tocopheryl) phosphate dipotassium salt, or a combination of any thereof; and (b) a compound selected from the group consisting of non-neutralised di-(tocopheryl) phosphate, non-neutralised di-(tocopheryl) phosphate monosodium salt, and non-neutralised di-(tocopheryl) phosphate monopotassium salt, or a combination of any thereof. 7. The method of claim 2 wherein the ratio (w/w %) of non-neutralised mono-(tocopheryl) phosphate to non-neutralised di-(tocopheryl) phosphate is about 4:1 to about 1:4. 8. The method of claim 2 wherein the non-neutralised tocol phosphate has a pH of less than about 4. 9. The method of claim 2 wherein the non-neutralised tocol phosphate comprises from about 0.01% w/w up to about 40% w/w of the total concentration of the composition. 10. The method of claim 2 wherein the vitamin A compound is selected from the group consisting of vitamin A, a derivative of vitamin A, a metabolite of vitamin A, a precursor of vitamin A, or pro-vitamin A, or a combination thereof. 11. The method of claim 2 wherein the vitamin A compound is a carotenoid. 12. The method of claim 11 wherein the carotenoid is selected from the carotene class including alpha-carotene, beta-carotene, gamma-carotene, beta-cryptoxanthin and lycopene. 13. The method of claim 2 wherein the ratio (w/w %) of non-neutralised tocol phosphate to vitamin A compound is from about 0.01:1 to about 100:1. 14. The method of claim 2 wherein the vitamin A compound is beta-carotene. 15. The method of claim 2 wherein the formulation further comprises a nutrient compound selected from the group consisting of antioxidants, vitamins, minerals and trace elements. 16. The method of claim 15 wherein the nutrient compound is selected from the group consisting of coenzyme Q10, ubiquinol, vitamin D compounds, vitamin E compounds, vitamin K compounds, folic acid, vitamin B compounds, vitamin C, vitamin P, vitamin F, lutein, zeaxanthin, cysteine, flavonoids, isoflavones, bilberry, ginkgo biloba, grape seed extract, phytonutrients, alpha lipoic acid, bilberry, bioflavinoids, unsaturated fatty acids, calcium, phosphorus, magnesium, fluorine, phosphorus, sulfur, sodium, potassium, chloride, calcium, iodine, cobalt, copper, iron, manganese, molybdenum, selenium, zinc, chromium, cadmium, fluorine, nickel, silicon, tin, vanadium, niacin, and combinations thereof. 17. The method of claim 2 wherein the hydrophobic delivery vehicle is an oil or a wax. 18. The method of claim 2 wherein the hydrophobic delivery vehicle is present in an amount of at least about 60.0% w/w of the total concentration of the formulation. 19. The method of claim 2 wherein the non-neutralised tocol phosphate has a pH of about 2 to about 4.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (88)
Terren Nadia,FRX ; Michelet Jacques,FRX ; Perrin Martine,FRX, Acidic composition based on lipid vesicles and its use in topical application.
Lhner Manfred (Bonn DEX) Posselt Klaus (Bonn DEX) Vogtle-Junkert Ute (Alfter DEX) Wagener Hans H. (Meckenheim DEX), Agents for the treatment of severe pain and preparation of said agents.
Challis Brian Christopher,GB3 ; Guthrie Walter Graham,GB3 ; Roper David Vincent,GB3 ; Trew David Frank,GB3, Chemical compositions for inhibiting nitrosation reaction in toiletries and cosmetics.
Kenneth B Kirby ; Berno I. R. Pettersson, Jr., Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof.
West, Simon Michael; Verdicchio, Robert J.; Kannar, David; Mills, Jr., Otto H., Dermal therapy using phosphate derivatives of electron transfer agents.
Lubkin Virginia (One Blackstone Pl. New York NY 10471), Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and appli.
Belly Robert T. (Ithaca NY) Scensny Patricia M. (Rochester NY) Wu Annie L. (Penfield NY) Chen Chung-yuan (Rochester NY), Hydrolyzable compounds which release electron transfer agents and analytical use of same.
Sanjay Kumar IN; Rashmita Sahoo IN; Paramvir Singh Ahuja IN, Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions.
Palepu, Nagesh; Kessler, Dean; Tustian, Alexander K.; Quay, Steven C.; Constantinides, Panayiotis P.; Lambert, Karel J., Method for treating colorectal carcinoma using a taxane/tocopherol formulation.
Ito Shinobu,JPX ; Ogata Eiji,JPX, Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals.
Lucas Juliet Marie ; Trinh Toan ; Dodd Michael Thomas ; Bartolo Robert Gregory, Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins.
Uphues Guenter (Monheim DEX) Ploog Uwe (Haan DEX) Bischof Klaudia (Werne DEX), Process for the production and isolation of monoalkyl phosphoric acid esters.
Baldwin William S. (Minneapolis MN) Willging Stephen M. (Minneapolis MN) Siegel Brock M. (Minneapolis MN), Production of d-alpha-tocopherol from natural plant sources.
Schor Joseph M. (Locust Valley NY) Nigalaye Ashok (Elmhurst NY) Gaylord Norman G. (New Providence NJ), Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose.
Manning Mark C. ; Randolph Theodore W. ; Shefter Eli ; Falk ; III Richard F., Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the s.
Bernard Dominique (Paris FRX) Nguyen Quang Lan (Antony FRX), Stabilized cosmetic or dermatological composition containing several precursors of the same active agent in order to max.
Bob G. Sanders ; Kimberly Kline ; Laurence Hurley ; Robb Gardner ; Marla Menchaca ; Weiping Yu ; Puthucode N. Ramanan ; Shenquan Liu ; Karen Israel, Tocopherols, tocotrienols, other chroman and side chain derivatives and uses therof.
Kurihara-Bergstrom Tamie (New City NY) Liu Puchun (Storrs CT), Transdermal administation of ionic pharmaceutically active agents via aqueous isopropanol.
Weissman Donald L. ; Rosenbaum Jerry, Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins.
Meybeck Alain (Courbevoie FRX) Bonte Frederic (Courbevoie FRX) Marechal Christian (Paris FRX), Use of a
상세보기
Meybeck Alain (Courbevoie FRX) Dumas Marc (Colombes FRX) Bonte Frederic (Courbevoie FRX) Marechal Christian (Paris FRX), Use of a tocopherol phosphate or one of its derivatives for the preparation of cosmetic or pharmaceutical compositions a.
Meybeck Alain (Courbevoie FRX) Dumas Marc (Colombes FRX) Bonte Frederic (Courbevoie FRX) Marechal Christian (Paris FRX), Use of a tocopherol phosphate or one of its derivatives, for the preparation of cosmetic or pharmaceutical compositions.
Stella Valentino ; Krise Jeffrey P. ; Zygmunt Jan J. ; Georg Ingrid Gunda, Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof.
Hong Jong Eon,KRX ; Lee Ki Hwa,KRX ; Cho Jun Chul,KRX ; Lee Jang Sob,KRX ; Lee Jung No,KRX ; Chun Ji Min,KRX ; Jang Dong Il,KRX ; Lee Ok Sob,KRX ; Lee Sang Rhin,KRX, Water-in-stable L-ascorbic acid derivative and a method for preparation thereof, and a skin-whitening cosmetic compositi.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.